Bile acid sequestrants (BAS) have been used for more than 50 years in the treatment of hypercholesterolemia. The last decade, bile acids are emerging as integrated regulators of metabolism via induction of various signal transduction pathways. Consequently, BAS treatment may exert unexpected side-effects. We discuss a selection of recently published studies that evaluated BAS in several metabolic diseases.
INTRODUCTION
Bile acids are amphipathic molecules that are synthesized in the liver from cholesterol. Until recently, they were considered to be simple detergents facilitating absorption of dietary fat and lipid-soluble vitamins. During the last decade, it has become clear that bile acids play an important role in the regulation of energy metabolism by acting as key signaling molecules, activating nuclear receptors and cell signaling pathways [1] .
Because bile acids are synthesized from cholesterol, their removal via sequestration in the intestine lowers LDL cholesterol (LDL-C) levels. Therefore, bile acid sequestrants (BAS) have been developed as a strategy to treat hypercholesterolemia. Interestingly, intestinal sequestration of bile acids also improves glycemic status in type 2 diabetes patients. Moreover, bile acid signaling influences energy expenditure. Modulating bile acid signaling via sequestration could, therefore, have multiple beneficial effects as therapy for the metabolic syndrome.
Novel aspects of bile acid metabolism and the effects of intestinal sequestration in basal and clinical research will be covered in this review.
Regulation of bile acid metabolism
Bile acids are formed from cholesterol via a multistep process in two parallel metabolic pathways. The neutral (classic) pathway starts with 7-a-hydroxylation of cholesterol by cholesterol a-hydroxylase (CYP7A1) and the acidic pathway is initiated by sterol 27-hydroxylase (CYP27A1). At the step catalyzed by hydroxy delta 5-steroid dehydrogenase, both pathways converge leading to the main endproduct cholic acid for the neutral pathway and chenodeoxycholic acid (CDCA) for the acidic pathway (see for review [1] ). Particularly, expression and activity of CYP7A1 is regulated via a complex mechanism. In contrast, little is known about the regulation of CYP27A1, despite its role in both pathways and severe phenotype in humans lacking this enzyme [2] . In rodents, CDCA is rapidly converted into the hydrophilic a-muricholic and b-muricholic acids.
Conjugation of bile acids prior to their secretion increases their solubility. Human bile acids are mainly conjugated to glycine [3] , whereas bile acids in rodents are almost exclusively taurine conjugated. Note that conjugated and most unconjugated bile acids are fully ionized at neutral pH and formally should be called bile salts. Bile salts are secreted via the bile salt export pump from the liver into bile and induce secretion of cholesterol and phospholipids from the canalicular space (see for recent review [1] ).
In the intestine, bacteria deconjugate bile salts and convert primary bile salts into secondary bile salts. In humans, portions of cholic acid and CDCA are converted into the secondary bile salts deoxycholic acid (DCA) and lithocholic acid (LCA), respectively. In mice, DCA is formed from cholic acid and b-muricholic acid is converted into v-muricholic acid. Vice versa, bile salts are known to have antimicrobial activity. Conditions with decreased bile salt secretion, such as liver cirrhosis, are associated with bacterial overgrowth [4] .
In the ileum and colon, about 95% of bile salts are reabsorbed (except for LCA) by both active and passive mechanisms (for review see [1] ). The reabsorbed bile salts are transported back to the liver via the portal venous circulation for resecretion into bile. This constant recycling of the bile salt pool is called the enterohepatic circulation. The remaining bile salts are lost in feces and are replenished by de novo synthesis from cholesterol in the liver. In humans, approximately 500 mg of bile salts are synthesized per day, being an important route for elimination of excess cholesterol.
Bile salts as signaling molecules
It has become clear that bile salts, in addition to solubilizing fat, act as important metabolic signaling molecules. Bile salts can activate nuclear receptors such as the farnesoid X receptor (FXR/NR1H4) and thereby modulate the transcription of genes involved in bile salt, cholesterol and glucose metabolism [5] [6] [7] . Furthermore, bile salts activate the G protein-coupled bile acid receptor 1 (TGR5/ GPBAR1) and (secondary) bile salts have been shown to activate the constitutive androstane receptor [8] , pregnane X receptor (PXR/NR1l2) [9] and vitamin D receptor [10] . PXR and the vitamin D receptor are involved in detoxifying bile salts as well as inhibiting bile salt synthesis [10] [11] [12] [13] .
Bile salts regulate their own synthesis via signaling through the nuclear receptor FXR in the liver and intestine. Bile salt activation of hepatic Fxr induces the expression of small heterodimer partner (Shp/Nr0b2) [14] . SHP functions as a potent repressor of the nuclear receptor liver homolog receptor-1 (Lrh-1/Nr5a2) [15] . Initially, in-vitro studies identified Lrh-1 as a critical transcription factor for Cyp7a1 [16] [17] [18] [19] [20] [21] . However, as liver-specific Lrh-1 gene deletion did not alter Cyp7a1 expression, the regulatory role of Lrh-1 on Cyp7a1 transcription remained controversial [19, 20] . Recently, it was shown that Lrh-1 is critical in vivo for the activation of Cyp7a1 as Lrh-1 knockdown mice could not increase bile salt synthesis during intestinal bile salt sequestration [18 & ]. Additionally, Lrh-1 controls bile salt synthesis by inducing Cyp8b1 transcription [19] [20] [21] ), hereby changing the pool composition. Thus, bile salt activation of hepatic Fxr via Shp prevents Lrh-1 from activating Cyp7a1 and Cyp8b1 and therefore inhibits bile salt biosynthesis. However, several studies suggest that hepatic Fxr is only activated when bile salt levels are pathologically elevated and under normal physiological conditions, intestinal Fxr mediates feedback regulation of bile salt synthesis [22, 23] .
When bile salts are taken up in the ileum, bile salt activation of intestinal Fxr induces the expression of FGF19 (fibroblast growth hormone 19) or Fgf15 (mouse ortholog of the human FGF19), a secreted protein that binds to the hepatic receptor KEY POINTS BAS have proven their efficacy in reducing plasma cholesterol levels in hypercholesterolemic patients for more than 40 years, as well as in reducing the risk of coronary heart disease.
The mechanisms underlying the glucose-lowering properties of BAS treatment are still under investigation, although the most feasible explanation involves the increase in incretin release during bile salt sequestration.
Recently, new insights emerge on the regulation and functions of the hormone Fgf15/FGF19, which is greatly affected by BAS treatment. In addition to the known effects on bile salt synthesis and gallbladder filling, Fgf15/FGF19 works, subsequent to insulin, as a postprandial regulator modulating several signaling pathways involved in fatty acid, glucose and energy metabolism.
More research needs to be performed to confirm other potential effects of BAS treatment, such as reducing the risk of gallstone formation, changing intestinal gut microbiota composition and regulating energy metabolism.
complex Fgfr4/b-Klotho. Via subsequent signal transduction, Cyp7a1 expression is repressed [24] [25] [26] [27] [28] . Concurrently, Fgf15/FGF19 decreases bile salt absorption by inhibiting the ileal apical sodiumdependent bile salt transporter (Asbt/Slc10a2) [29] . Thus, bile salts regulate their own synthesis from two distinct sites in the body. Recently, it was shown that the intestinal Fxr-mediated Fgf15 production contributes to the regulation of hepatic bile salt synthesis in mice mainly during the dark phase [30 & ]. However, Fxr-independent mechanisms are likely to play a role in regulating Fgf15 production, as intestinal Fxr À/À mice are still able to upregulate Fgf15 and downregulate Cyp7A1 expression upon TCA feeding [30 & ]. There might be a role for Lrh-1 herein, as Fgf15 expression is decreased in Lrh-1 knockdown and intestinal-specific Lrh-1 knockout mice [18 & ,20 ]. Furthermore, it remains to be investigated whether Lrh-1 might be involved in the downstream signaling cascade of Cyp7A1 repression by Fgf15/FGF19.
There is a tight relation between bile salt and cholesterol metabolism. When cholesterol is converted into bile salts, hepatic microsomal cholesterol content decreases. This causes upregulation of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase (HMGCR) and increases LDL receptor (LDLR), as their expression is controlled by the sterol-sensing sterol regulatory element-binding proteins (SREBPs) [31] . Consequently, more cholesterol is synthesized de novo and recruited from plasma LDL particles to deliver sufficient substrate for bile salt synthesis. Thus, modulation of hepatic cholesterol conversion into bile salts serves as a key mechanism by which bile salts can impact on plasma cholesterol levels.
In addition, bile salts can bind to TGR5/ GPBAR1. The most potent natural agonist is LCA, but several other bile salts such as DCA, CDCA and cholic acid are able to activate TGR5. TGR5 is expressed in multiple organs lining the enterohepatic axis, such as gallbladder, cholangiocytes and intestine. Tgr5 -/mice showed a decreased total bile salt pool size, for which the mechanism is still unknown. Furthermore, TGR5 is expressed in several organs important for energy homeostasis such as brown adipose tissue (BAT) and skeletal muscle (reviewed in [32] ).
Thus, as bile salts are important signaling molecules modulating bile salt homeostasis, they could serve as an attractive target to treat several conditions associated with the metabolic syndrome.
BILE ACID SEQUESTRANTS
BAS are large polymers that bind negatively charged bile salts in the small intestine. Binding of bile salts in the intestine disrupts their enterohepatic circulation by preventing reabsorption from the gut, hence increasing their fecal excretion up to more than three times the normal [33] . Consequently, bile salt synthesis is increased at the expense of plasma LDL-C concentrations. The cholesterol-lowering action of these drugs, thus, appears to be mainly mediated through increased bile salt excretion. Therefore, these compounds have been used as cholesterol-lowering agents since the early 1960s.
Three compounds are available on the market: cholestyramine, colestipol (first-generation BAS) and colesevelam-HCl. Cholestyramine and colestipol have greater affinity for dihydroxy than trihydroxy bile salts, which in time creates an imbalance in the bile salt pool by increasing the trihydoxy bile salt fraction. In contrast, colesevelam-HCl has been specifically engineered to bind bile salts via both hydrophobic and ionic sites, which enhances the affinity and specificity to bind bile salts compared to the traditional BAS and allows it to be used at lower doses [34, 35] .
BAS are considered safe although they are associated with gastrointestinal complaints (e.g., constipation, abdominal pain, nausea, etc.) which often results in treatment discontinuation. Furthermore, BAS can decrease the absorption of fat, fat-soluble vitamins and other nutrients, which should be considered during long-term treatment [36] [37] [38] . In addition, cholestyramine and colestipol may affect the absorption of several drugs, which may become dangerous in case of drugs with a narrow therapeutic window, such as warfarin. In contrast, studies using colesevelam-HCl treatment reported less side-effects and drug interactions than the traditional BAS [35, 39] . Finally, BAS treatment often results in increased triglyceride levels, which limits the use of these compounds in patients with high plasma triglyceride levels [34] .
Cholesterol-lowering properties
BAS have been used for more than four decades as cholesterol-lowering agents in the treatment of dyslipidemias. As monotherapy, these compounds have proven their efficacy in reducing LDL-C levels by 9-28% without changing or slightly increasing HDL-cholesterol (HDL-C) by 0-9% in a dosedependent manner (for review see [40] ). In addition, BAS have also been used in combination with other lowering drugs (such as statins, niacin, fibrates and ezetimibe) in order to achieve stronger LDL-C-lowering effects (Table 1) .
Bile salts influence plasma triglyceride levels by inhibiting the production of triglyceride-rich very low density lipoprotein (VLDL) particles and accelerating their clearance from the circulation (reviewed in [60] ). The impact of BAS on triglyceride metabolism is partly mediated by Fxr. BAS treatment changes the bile salt pool composition towards a pool composed of less potent Fxr agonists [61 & ]. Therefore, reduced Fxr activity influences the transcription of several genes involved in triglyceride metabolism, such as ApoC-II [a component of VLDL which activates lipoprotein lipase (Lpl) in capillaries] [62] . Indirectly, Fxr also decreases triglyceride synthesis via Shp by inhibiting Srebp1c expression and the Fxr target gene Fgf15/FGF19 has been reported to induce fatty acid oxidation [63, 64] . Accordingly, Fxr À/À mice develop severe fatty liver and elevated circulating free fatty acid, plasma cholesterol and triglyceride levels [65, 66] , whereas Fxr activation by feeding a cholic acid diet [62, 67] or administration of a synthetic Fxr agonist GW4064 [67] prevents hypertriglyceridemia. Thus, by attenuating FXR activation, bile salt sequestration impairs triglyceride metabolism.
One could speculate that BAS treatment in addition to reducing bile salt (re)absorption could also reduce cholesterol absorption, as cholesterol needs to be incorporated into mixed micelles in order to be absorbed. However, the fact that combined treatment of BAS with ezetimibe has additive effects in reducing plasma LDL-C levels, discards this hypothesis. Furthermore, it is likely that binding between BAS and bile salts takes place in the lower small intestine when the acidic pH of the stomach content has been neutralized. Therefore, micelle formation and cholesterol absorption can still take place in the upper small intestine. Taken together, the use of BAS as monotherapy or in combination with other cholesterol-lowering agents will depend on the sensitivity and tolerability of the patients to these drugs.
Cholesterol-lowering treatment is often initiated to reduce the risk of atherosclerosis and cardiovascular diseases, which can lead to ischemic heart disease and stroke. Cholestyramine and colestipol (either as monotherapy or in combination with other cholesterol-lowering agents) have proven their efficacy in reducing the risk of coronary heart disease which is related to the degree of LDL-C reduction and HDL-C increase ( Table 2) . Although the effects of colesevelam-HCl on reducing the risk of coronary heart disease have not yet been addressed, colesevelam-HCl treatment has been successful in decreasing the total amount of LDL particles, increasing LDL particle size [68] and decreasing the levels of high-sensitive C-reactive protein [69, 70] , markers of cardiovascular risk and inflammation, respectively. 
Bile acid sequestrants in diabetes
Type 2 diabetes mellitus (T2DM) is currently an epidemic disease worldwide. The initial treatment of T2DM consists of weight loss, control of hypertension, management of dyslipidemia as well as lifestyle modifications. However, if this is insufficient, a pharmacological approach must be established. Currently, there are 12 antidiabetic drugs available (including insulin) that target different pathological defects. Among them, colesevelam-HCl has been approved as an adjuvant to diet and exercise interventions in order to improve glycemic control in patients with T2DM.
One of the first studies that reported the beneficial effects of cholestyramine in type 2 diabetes appeared in the mid-1990s. Cholestyramine treatment (8 g/day for 6 weeks) achieved reductions in fasting plasma glucose of around 13% [71] . Since then, the efficacy of BAS alone or in combination with other antidiabetic drugs (e.g., insulin, sulfonylurea or metformin) on improving glucose control has been tested in several clinical trials ( Table 3 ). The glucose-lowering effects of colesevelam-HCl treatment used as monotherapy was tested in a 16-week, randomized, double-blind study in adults with untreated prediabetes [72] . As expected, colesevelam-HCl treatment reduced LDL-C, total cholesterol and apolipoprotein B levels. Additionally, fasting plasma glucose and HbA 1c were reduced (À4% and À2%, respectively). The combination of colesevelam-HCl with other antidiabetic drugs achieved additive reductions in fasting plasma glucose and HbA 1c of around 10% [61 & , [75] [76] [77] [78] . The efficacy of other BAS (colestimide and cholestyramine) in improving glycemic control has been addressed in two different studies. Treatment resulted in both reductions in fasting plasma glucose and HbA 1c of around 10% [71, 73] .
The exact mechanism of how BAS improve glycemic control has not been fully defined yet; however, multiple hypotheses have been proposed [79] [80] [81] . One of the proposed mechanisms is based on the ability of BAS to alter the composition of the bile salt pool [1, 79, 82] . In a recent study, bile salt pool sizes and synthesis rates were determined before and after 8 weeks of colesevelam-HCl treatment in patients with T2DM and in healthy controls [61 & ]. Although colesevelam-HCl treatment resulted in a more hydrophilic bile salt pool, no associations were found between these bile salts and glucose levels. It has been speculated that changes in bile salt pool composition may result in changes in FXR activity, which may result in improving insulin resistance [83] . However, this could not be confirmed in two different studies in diabetic rats receiving BAS [84 & ,85] .
A second proposed mechanism involves increased release of incretins after BAS treatment [84 & , 85,86,87 & ]. The decrease in bile salt reabsorption caused by BAS treatment might increase the luminal concentration of bile salts which in turn would be able to activate TGR-5 [88, 89] . This activation would ultimately stimulate the release of incretins such as glucagon-like protein 1 (GLP-1) [88] , a potent glucose-lowering hormone produced in enteroendocrine L cells. GLP-1 is secreted into the blood and increases glucose-stimulated insulin release, likely by increasing the sensitivity of pancreatic b-cells to glucose [ ]. T2DM patients treated with colestimide had increased 2-h postprandial GLP-1 levels [87 & ], whereas plasma glucose levels decreased. Similarly, treatment of type 1 diabetic patients with colesevelam-HCl resulted in reductions in HbA 1c , which were inversely related to increased GLP-1 levels [91] . Thus, the increase in incretin release could be responsible for the observed decrease in fed serum glucose and increase insulin after BAS treatment, which is associated with improved insulin sensitivity.
In addition, it has been proposed that BAS treatment is able to modulate hepatic glucose metabolism [83] , although the available data are contradictory. On the one hand, several studies indicate that bile salts suppress expression of genes involved in gluconeogenesis and decrease blood glucose levels [92] [93] [94] . Bile salts modulate hepatic glucose metabolism via signaling pathways mediated by the nuclear receptor Fxr [92, 95] . Fxr-null mice exhibit elevated serum glucose levels and impaired glucose tolerance and insulin sensitivity [96] . Moreover, activation of Fxr by GW4064 or hepatic Fxr overexpression lowered blood glucose levels in both diabetic db/db and wild-type mice [97] . This effect was the result of repression of hepatic gluconeogenic genes and increased hepatic glycogen synthesis and glycogen content, while increasing insulin sensitivity [97] . On the other hand, recently it has been shown that long-term Fxr activation by GW4064 reduced basal energy expenditure and resulted in glucose intolerance and insulin resistance, whereas cholic acid administration had opposite effects. The authors hypothesized these effects to be due to differences in bile salt pool size and decreased Tgr5 activation, although plasma bile salts were unchanged [98] . The glucose-lowering effects of bile salts may be mediated by Fgf15/FGF19. Kir showed that Fgf15-null mice exhibit enhanced blood glucose levels after an oral glucose bolus and decreased postprandial liver glycogen storage. Like insulin, Fgf15/FGF19 inhibits hepatic gluconeogenesis [100 & ] and FGF19 was shown to increase glucose uptake in 3T3-L1 adipocytes [26] . Moreover, treatment with FGF19 prevented or even reversed the development of diabetes in two different mouse models [64] . However, unlike FGF19, treatment of ob/ob mice with an FGF19 variant with selective activation of Fgfr4 failed to improve glucose levels and insulin sensitivity [101] . Taken together, it is conceivable that changes in FXR activity resulting from BAS treatment may affect hepatic glucose fluxes. The exact mechanism, however, still needs to be elucidated.
Finally, it has been speculated that BAS may decrease glucose absorption in the intestine [102] . However, this could not be confirmed in in-vivo studies [61 & ,103] . In a recent pilot study, the effects of colesevelam-HCl on insulin sensitivity and potential binding to glucose were assessed in T2DM patients [103] . Colesevelam-HCl treatment improved whole-body insulin resistance, although not by altering glucose absorption. Therefore, it seems unlikely that the glucose-lowering effects of BAS therapy are because of changes in glucose absorption in the intestine.
Bile acid sequestrants in energy metabolism
Recent data from mouse studies suggest a role for bile salts on energy metabolism. A diet enriched in cholic acid has been shown to increase energy expenditure and prevented diet-induced obesity [104] . This effect was mediated by activation of BAT. Bile salt signaling through Tgr5 activated the enzyme deiodinase iodothyronine type 2 (D2) that converts the inactive thyroid hormone thyroxine into its active form, hereby increasing thyroid hormone receptor saturation. Furthermore, peroxisome proliferator-activated receptor gamma coactivator 1-alpha (Pgc-1a) was activated, which is a master regulator of mitochondrial biogenesis [104] . During high-fat feeding, female Tgr5 À/À mice gained more weight than controls. Moreover, administration of the Tgr5 agonist INT-777 resulted in attenuation of weight gain as a consequence of enhanced energy expenditure [32, 105] .
On the basis of mouse data, the role of bile salts in modulating (postprandial) energy metabolism would suggest that long-term BAS treatment would result in decreased energy expenditure and fat accumulation. To date, only one study investigated the relationship between plasma bile salt levels and energy expenditure in patients with T2DM and healthy controls before and after BAS treatment. Total plasma bile salts tended to be lower in T2DM; however, no differences were found in resting energy expenditure (REE) between T2DM and controls at baseline or after BAS treatment, neither did plasma bile salts correlate with REE [106] . More research needs to be performed in order to define the role of bile salts and their sequestration in regulating energy expenditure in human populations.
Other signaling by bile salts (possible effects of bile acid sequestrants) BAS treatment results in a more hydrophillic bile salt pool, which is associated with decreased susceptibility for gallstone disease [107] . Hydrophobic bile salts activate Tgr5 and decrease gallbladder smooth muscle function, which is a hallmark of gallbladder disease [108 & ]. It has been shown that Tgr5 -/mice fed a lithogenic diet are protected against cholesterol gallstone formation [109] . A shift towards a more hydrophillic bile salt pool during BAS treatment might therefore lead to decreased TGR5 activation in the gallbladder which could protect against gallstone disease. In addition, the intestinal Fxr target gene Fgf15/FGF19 stimulates gallbladder filling, possibly involving the fibroblast growth factor receptor 3 [110] . The fact that Fgf15/FGF19 is decreased during BAS treatment may contribute to diminished gallbladder relaxation. Therefore, BAS treatment might be beneficial for preventing gallstone formation, which has an increased prevalence in type 2 diabetic patients [111] .
Furthermore, binding bile salts might interfere with their antimicrobial actions which might lead to bacterial overgrowth. Bacteria are known to have great impact on bile salt, cholesterol and glucose metabolism (reviewed in [112] ). The composition of the gut microbiota is linked to energy extraction from the diet, synthesis of gut hormones involved in energy homeostasis, production of butyrate and the regulation of fat storage [112] . Therefore, it is increasingly acknowledged that gut microbiota might contribute to the pathophysiology of obesity and T2DM, as these patients exhibit a different bacterial flora (reviewed in [113] ). Thus, studies are warranted to investigate the effects of BAS treatment on gut microbiota composition.
CONCLUSION
Bile salt sequestration has major beneficial effects on disturbed human metabolism, it lowers LDL-C and ameliorates hyperglycemia in T2DM patients, thus seems a treatment of choice in disorders such as the metabolic syndrome. Yet, some future challenges remain in deciphering the mechanisms responsible for the glucose-lowering effects of BAS and exploring possible consequences on energy metabolism, gallstone disease and gut microbiota composition.
